Differences in biological behaviors and clinical treatment between colon and rectal cancers
Article
Figures
Metrics
Preview PDF
Reference
Related
Cited by
Materials
Abstract:
[Abstract] At present, more and more evidence shows that colon and rectal cancers are different diseases. There are many differences no matter in the epidemiology, anatomy and histology, molecular characteristics, transfer patterns, or clinical treatment methods, therapeutic effects and prognosis. In clinical treatment, it cann’t be considered as the same disease in general. Through the retrospective analysis of the three clinical studies of CALGB/SWOG 80405, CRYSTAL, and FIRE-3, it has been found that there were significant differences in the efficacy of cetuximab and bevacizumab in left and right colon cancer. Based on the above clinical trials, the National Cancer Institute for the United States (NCCN) for the first time includes the guidelines for the impact of primary sites on the treatment of colon cancer into guidelines in 2017. In the current era of advocating precision and individualized treatment, to clarify the pathogenesis,histological differences and clinical response to drugs in colon cancer and rectal cancer, can not only reduce the economic burden of patients,but also provide the most scientific basis for the precise treatment of patients gradually.
Keywords:
Project Supported:
Project supported by the Natural Science Foundation of Shanghai(No. 10ZR1438100,No. 04ZR14003), and the Key Project of Natural Science Foundation of Shanghai(No. 06DZ19505)